Sun Pharmaceutical Recalls Bupropion Hydrochloride Tablets for Dissolution Failures
Sun Pharmaceutical Industries is recalling 31,762 bottles of Bupropion Hydrochloride Extended-Release Tablets because they failed dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard is a failure to meet dissolution specifications, which is a quality control issue rather than a direct safety threat like contamination or mislabeling.
Plain-English summary
Sun Pharmaceutical Industries, Inc. is recalling 31,762 bottles of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), 150 mg, Twice-A-Day. The affected product is distributed in 60-count bottles and is available by prescription only. The recall is limited to specific lot codes JKN5124A and JKN5229A with an expiration date of 10/2016.
The recall was initiated because the tablets failed to meet dissolution specifications. Dissolution testing ensures that a drug releases its active ingredient at the appropriate rate and amount in the body. When these specifications are not met, the medication may not work as intended.
The affected product was distributed nationwide. Consumers who have this medication should check their bottles for the specific lot codes and expiration date listed above. If the product matches the recall details, patients should contact their healthcare provider or pharmacist for guidance on how to proceed.
The recalled product
- Product
- BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
- Brand
- BUPROPION HYDROCHLORIDE
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 31,762
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- JKN5124A and JKN5229A
- exp 10/2016
UPCs (3)
- 0347335738865
- 0347335737868
- 347335737868
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPROPION HYDROCHLORIDE
- ModerateBupropion extended release tablets recalled after failing tablet specifications
FDA (Drugs) · 2025-10-29
- HighBupropion Extended-Release Tablets Recalled for Dissolution Failure
FDA (Drugs) · 2024-07-17
- HighFDA recalls Bupropion Hydrochloride tablets for foreign tablet contamination
FDA (Drugs) · 2024-01-17
- ModerateBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-12-13
- ModerateSun Pharmaceutical Bupropion Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-10-25
Same manufacturer · Sun Pharmaceutical Industries, Inc.
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17